Comprehensive Metabolic Empowerment: Unveiling Tirzepatide's Multifaceted Functions

Page 1

ComprehensiveMetabolicEmpowerment: UnveilingTirzepatide'sMultifacetedFunctions

WhatisTirzepatide?

TirzepatideisanovelmedicationthatisFDAapprovedforthetreatmentoftype2 diabetesmellitusGivenitspotentweightlossproperties,buytirzepatidebeused off-labelforobesitytreatment

ItworksasadualGLP-1agonistandGIPagonisttomaximizesimilarbenefitsthat areseenwithGLP-1medicationssuchassemaglutide.Itiscurrentlyimplementedas asecond-linediabetesmedication,similartoGLP-1medications,andgivenasa once-a-weeksubcutaneousinjectable.TheFDAapprovedpeptideTirzepatideinMay 2022.

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com king@aasraw.com

HowDoesTirzepatideWork?

Tirzepatideisasyntheticpeptide;andadualgastricinhibitorypolypeptide(GIP)and glucagon-likepeptide1(GLP-1)receptoragonist.Itiscomposedof39aminoacids andisananalogofthegastricinhibitorypolypeptide.Functionally,itstimulates insulinreleasefromthepancreasandleadstoareductionofhyperglycemia.In addition,Tirzepatidealsoincreasesthelevelsofadiponectin.Itsdualagonismability leadstoamoresignificantreductionofhyperglycemiathanGLP-1agonistagents aloneandlowerstheuser'sappetite.

TirzepatideBenefits

Tirzepatideisaglucose-dependentinsulinotropicpolypeptide(GIP)receptorand glucagon-likepeptide-1(GLP-1)receptoragonist,whichisFDA-approvedfortreating type2diabetesmellitus.Itisimportanttonotethattirzepatideisnotapprovedfor treatingtype-1diabetesmellitusandhasnotbeenstudiedinpatientswith pancreatitis.TirzepatideisaGIPreceptorandGLP-1receptoragonist,leadingto significantlyimprovedglycemiccontrolintype2diabeticsandsignificantweight reduction.

TirzepatideResults

Patientswithobesityandtype2diabetes(T2D)orwithoverweightandT2Dlostan

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com
king@aasraw.com

estimated344pounds(157%)ofbodyweightwith10mgand15mgoftirzepatide (Mounjaro;EliLillyandCompany),accordingtofindingsfromtheSURMOUNT-2 globalphase3trialSpecifically,tirzepatideat10mgreducedbodyweightby5%or morein792%ofpatientsandreducedaveragebodyweightby128%,whilethe15 mgdosereducedweightin827%ofpatientsanddecreasedaveragebodyweight by14.7%.

TirzepatideusedforWeightLoss

Tirzepatide,isaonce-weeklyinjectiontodecreasebloodsugar.Since2022ithas shownremarkableweight-losseffects,andisonfast-trackdesignationforitsreview forthetreatmentofobesity.Onaverage,patientssawanastoundingweight-lossof over20%oftheirinitialbodyweight.

TirzepatideandBPC157helpswithweightlossbydecreasingfoodintakeand slowingdownhowfastfoodtravelsthroughyourdigestivetractThismayhelpyou feelfullerlongerandreducehowmuchfoodyoueatStudiesshowthisactionmay occurinthebrain

Howitworks:

●Reducehowmuchfoodiseaten.

●Stopstheliverfrommakingandreleasingtoomuchsugar.

king@aasraw.com

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com

●Slowsdownhowquicklyfoodleavesthestomach

●Thebodyreleasesinsulinwhenbloodsugarishigh

●Thebodyremovesexcesssugarfromtheblood

WhatisthedifferencebetweenTirzepatideandSemaglutide?

TirzepatideactsonBOTHGIPandGLP-1receptors,whileSemaglutideactsonlyon GLP-1receptors.Bothdrugsareeffectiveweight-losstreatments.Tirzepatideisa dual-actingGIP(glucose-dependentinsulinotropicpolypeptide)andGLP-1 (glucagon-likepeptide-1)receptoragonist.Bothareintheclassofdrugsknownas incretinmimeticsbuthavesomedifferences.

Lifestylemodificationsandcalorierestrictionwillleadtooverallbetterresults. Benefitsofweightlossisimprovedcomorbiditiesofobesitysuchasdiabetes,high bloodpressure,abnormalbloodlipidsandheartdiseasewhichcanbeseenwithas littleasa5%weightloss

TirzepatideSideEffects

ThemostcommonsideeffectsofTirzepatideincludenausea,diarrhea,decreased appetite,vomiting,constipation,indigestion,andstomach(abdominal)pain.These arenotallthepossiblesideeffectsofTirzepatide.Talktoyourhealthcareprovider

king@aasraw.com

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com

aboutanysideeffectsyoumightexperience

References

[1]Lilly:Phase3TirzepatideResultsShowSuperiorA1CAndBodyWeight ReductionsInType2Diabetes"BusinessInsiderRTTNews19October2021 Archivedfromtheoriginalon28October2021.Retrieved28October2021.

[2]TirzepatidesignificantlyreducedA1Candbodyweightinpeoplewithtype2 diabetesintwophase3trialsfromLilly'sSURPASSprogram"(Pressrelease).Eli LillyandCompany.17February2021.Archivedfromtheoriginalon28October2021. Retrieved28October2021–viaPRNewswire.

[3]Kellaher,Colin(28April2022)."EliLilly'sTirzepatideMeetsMainEndpointsin Phase3ObesityStudy".MarketWatch.DowJonesNewswires.Archivedfromthe originalon29April2022.Retrieved29April2022.

[4]WillardFS,DourosJD,GabeMB,ShowalterAD,WainscottDB,SuterTM,etal. (September2020)"TirzepatideisanimbalancedandbiaseddualGIPandGLP-1 receptoragonist"JCIInsight5(17)doi:101172/jciinsight140532PMC7526454 PMID32730231

king@aasraw.com

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com

[5]FrederickMO,BoyseRA,BradenTM,CalvinJR,CampbellBM,ChangiSM,etal (2021)"Kilogram-ScaleGMPManufactureofTirzepatideUsingaHybrid SPPS/LPPSApproachwithContinuousManufacturing"OrganicProcessResearch &Development25(7):1628–1636

[6]FríasJP,DaviesMJ,RosenstockJ,PérezManghiFC,FernándezLandóL, BergmanBK,etal.(August2021)."TirzepatideversusSemaglutideOnceWeeklyin PatientswithType2Diabetes".TheNewEnglandJournalofMedicine.385 (6):503–515.doi:10.1056/NEJMoa2107519.

king@aasraw.com

AASrawBiochemicalTechnologyCo.,ltd www.aasraw.com

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.